Search Results

The coming flu season is the clearest indication yet that biopharma’s long-standing assumptions about predictability, prevention and portfolio structure are no longer guaranteed.

Rentschler Biopharma SE announced that Patrick Cushing, Ph.D., has been promoted to Vice President Operations of Rentschler Biopharma, Inc., the company’s U.S. subsidiary, effective May 1, 2024.

Rentschler Biopharma SE, a leading contract development and manufacturing organization for biopharmaceuticals, including Advanced Therapy Medicinal Products, announced that Gunnar Voss von Dahlen has been appointed as Chief Financial Officer, effective December 1, 2023.

Rentschler Biopharma SE, a leading global contract development and manufacturing organization for biopharmaceuticals, including advanced therapy medicinal products, announced that Patrick Meyer, Ph.D., has been promoted to Global Head BD Sales and Alliance Management within the business development team, effective June 1, 2024.

Rentschler Biopharma SE, a leading contract development and manufacturing organization for biopharmaceuticals, including advanced therapy medicinal products, announced that Senta Brandt has been promoted to the global position of Head of Transformation, effective January 1, 2024.

While the FDA continues to put out guidance documents and approve drugs, some companies are already reporting delays in dealings with the agency, while insiders warn of falling morale and a negative perception from the rest of the biopharma world.